ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
Ultrasound-guided percutaneous core biopsy of renal sinus masses: diagnostic yield, safety, and clinical impact.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRenal sinus lesions present diagnostic challenges due to their complex anatomy and heterogeneous pathology. Reliable tissue acquisition is essential for guiding treatment decisions, yet evidence on the performance of ultrasound (US)-guided biopsy in this setting remains limited.
objectiveTo evaluate the diagnostic yield, safety profile, and clinical impact of US-guided percutaneous core needle biopsy(CNB) for renal sinus masses at a tertiary care center.
methodsWe conducted a retrospective analysis of 51 patients who underwent US-guided percutaneous CNB for indeterminate renal sinus masses between 2010 and 2020. Diagnostic yield, histopathological results, complication rates (graded by Clavien-Dindo classification), and subsequent changes in clinical management were assessed. Univariate logistic regression was employed to identify factors associated with complications.
resultsBiopsy achieved a diagnostic yield of 90.2% (46/51). Malignant lesions accounted for 88.2% of cases, most commonly upper-tract urothelial carcinoma (43.1%) and clear cell renal cell carcinoma (31.4%). Benign lesions comprised 11.8%. The overall complication rate was 7.8% (4/51), limited to grade I–II events (perirenal hematoma, hematuria); no major complications or needle tract seeding were observed. Biopsy findings altered treatment in 23.5% of patients, and unnecessary surgery was avoided in 7.8%. Tumor size, location, and number of needle passes were not significantly associated with complications (all P > 0.05).
conclusionUS-guided percutaneous CNB of renal sinus masses is a safe and effective diagnostic approach, providing high tissue yield with low morbidity. By enabling accurate diagnosis and reducing overtreatment, this technique represents a valuable tool in the management of complex renal tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.